Grant of Incentive Subscription Rights in IDEX Biometrics 9 November 2022
The board of directors of IDEX Biometrics ASA resolved on 9 November 2022 to issue 2,470,000 incentive subscription rights to 15 new and continuing employees and individual contractors in the IDEX Biometrics group. The grant was made under the company's 2022 incentive subscription rights plan as resolved at the annual general meeting on 12 May 2022. The exercise price of the subscription rights is NOK 1.03 per share. The subscription rights vest by 25% per year over four years and expire on 12 May 2027. Following the grants there are 83,111,447 incentive subscription rights outstanding in IDEX Biometrics.
For further information contact:
Marianne Bøe, Head of investor relations
Tel: + 47 9180 0186
About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint identification technologies offering simple, secure, and personal touch-free authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices, or gain admittance to buildings with the touch of a finger. We invent, engineer, and commercialize these secure, yet incredibly user-friendly solutions. Our total addressable market represents a fast growing multi-billion-unit opportunity.
For more information, visit www.idexbiometrics.com and follow on Twitter @IDEXBiometrics
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Savosolar appoints Kirsi Suopelto as Vice President, Strategy8.12.2022 10:30:00 CET | Press release
Savosolar Plc Company Announcement 8 December 2022 at 10.30 a.m. (CET) Savosolar appoints Kirsi Suopelto as Vice President, Strategy Savosolar has appointed Ms. Kirsi Suopelto, Master of Laws and MBA (born 1976) as Vice President, Strategy of Savosolar Plc and a member of the group's executive management team. Kirsi's tasks include preparation of large investments and financial arrangements as well as M&A projects. Kirsi was elected as the chairperson of the board of Savosolar Plc at the extraordinary general meeting held on November 25, 2022 and at the subsequent organizational meeting of the board. Kirsi has more than 20 years of experience in the financial industry, both in legal and commercial positions. Kirsi has worked for several companies offering financial services in Finland and abroad. She has also been promoting financial industry interests. Kirsi is the chairperson of the board, owner and founder of Hybrid Consulting Oy, which acted as an advisor to VG-Shipping Oy and Meri
Clinigen notes results from the MIROCALS trial investigating low dose Proleukin® (aldesleukin) in patients with amyotrophic lateral sclerosis8.12.2022 10:12:00 CET | Press release
8 December 2022 Clinigen notesresults from the MIROCALS trial investigating low doseProleukin® (aldesleukin)in patients withamyotrophic lateral sclerosis Clinigen Limited (‘Clinigen’), the global pharmaceutical services company, is pleased to notethe announcement of top-line results from MIROCALS (Modifying Immune Response & OutComes in Amyotrophic Lateral Sclerosis) a phase 2b randomised placebo-controlled trial investigating the efficacy and safety of low dose interleukin-2 (ld IL-2) for controlling neuro-inflammation in newly-diagnosed patients with amyotrophic lateral sclerosis (ALS). The MIROCALS trial, conducted in 220 patients from 17 clinics across the UK and France, in collaboration with eight leading research groups in the UK, France, Italy and Sweden, investigated whether low dose IL-2 can modify aspects of neuro- inflammation, which is believed to play a central role in ALS disease progression. Dr. Gilbert Bensimon presented the top-line results at the International Symposi
Kvika banki hf.: Birkir Jóhannsson new CEO of TM8.12.2022 10:01:44 CET | Press release
Birkir Jóhannsson has been appointed CEO of TM, Kvika banki‘s subsidiary. Birkir will be replacing Sigurður Viðarsson as he takes up the position of deputy CEO at Kvika. Birkir has in past years worked as managing director of core operations and digital solutions at VIS Insurance and has substantial work experience within banking, payment solutions and finance. Birkir has previously been employed at Birti Capital Partners, Valitor, Arion bank and Attorneys atHöfðabakki.. Birkir holds a law degree from the University of Iceland and a master’s degree in corporate finance from Reykjavik University. In addition, Birkir has completed a degree in securities trading and is licensed as a district court attorney. Birkir will be a member of the Kvika group management board. When the changes, that Kvika banki introduced on 5 December, have been implemented the Kvika group management team will consist of Kvika banki’s management board, the CEO of TM, the CEO of Kvika asset management and the CEO o
EV-Joyment, Emotional Promise Motivate EV Adoption Over Environmental Benefits8.12.2022 10:00:58 CET | Press release
Latest Escalent EVForward™ Europe report findings encourage brands to tap into emotional aspirations of BEV ownership to engage with consumers LIVONIA, Mich., Dec. 08, 2022 (GLOBE NEWSWIRE) -- As new-car buyer personas continue to evolve, connecting with consumers’ emotions and personality is more likely to ignite interest in battery electric vehicles (BEVs). This diverges from the long-standing industry narrative that environmental benefits are what drive BEV adoption, creating great opportunity for brands to expand their messaging and embrace new customers with a varying mix of values, lifestyles and attitudes. The environmental and running cost credentials of BEVs are clear, but relatively few car buyers are motivated by such a narrow range of rational criteria. In 2022, 43% of car buyers acknowledge the environmental credentials of BEVs as a benefit, but the same factor only ranks 9th out of 19 in a hierarchy of most important car buying criteria, thus revealing the environment’s l
Two rental housing trends reflected in SATO data too: Rental housing in city centres and residential districts remains popular − Most rental households have one or two members8.12.2022 10:00:00 CET | Press release
SATO Corporation Press release 8 December 2022 at 11.00 am The most popular residential areas are found in growth centre districts and areas close to city centres. One in three SATO tenants live alone. In late October, Statistics Finland released data on types of housing in Finland*, with two trends emerging from the statistics: the number of both those renting a home and those living alone is increasing. These trends can also be seen in data collected by SATO, one of Finland’s largest rental housing providers**. Population growth continues in the Helsinki Metropolitan Area, Tampere and Turku, and already almost half of the households in these cities live in a rental home. There are several reasons behind the popularity of renting a home in growth centres, including demographic change, the uncertainties of working life and the differentiated price development of owner-occupied homes: Outside growth centres, the real prices of homes are declining, which makes acquiring an owner-occupied